AbbVie Announces First Regulatory Approval of SKYRIZI(TM) (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan

This marks the first regulatory approval globally for SKYRIZI™ (risankizumab) SKYRIZI is a humanized immunoglobulin G1 (IgG1) monoclonal antibody designed to selectively inhibit IL-23 by binding to its p19 subunit[1] NORTH CHICAGO, Ill., March 26, 20... Biopharmaceuticals, Regulatory AbbVie, SKYRIZI, risankizumab, plaque psoriasis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news